Novel Biomarkers for Alzheimer's Disease
- Detailed Technology Description
- Executive Summary Early detection of Alzheimer’s disease (AD) is currently still difficult and inconclusive. New, non-invasive diagnostic tools to diagnose this widespread disease are heavily researched, as earlier and better diagnostics will alleviate many stressors for the patient and improve treatment options. Researchers at MSU have identified a new promising biomarker. This biomarker can be easily detected in the cerebrospinal fluid of patients, and can help rule out other causes of cognitive impairment. Description of Technology Amyloid beta peptide is a hallmark peptide in the etiology of AD. It has been shown that AD patients exhibit enhanced levels of glycopeptides compared to non-AD patients. MSU researchers now identified the exact structure of an amyloid beta glycopeptide. This novel biomarker can be used to allow earlier, more sensitive and empowered detection of AD. Key BenefitsEarly detection of Alzheimer’s diseaseHigher diagnostic accuracyPossible exclusion of other causes of cognitive impairment ApplicationsBiomarker diagnostics for Alzheimer’s disease Patent Status: Under review Licensing Rights Available Full licensing rights available Inventors: Xuefei Huang, Peng Wang, Goran Larson, Jonas Nilsson Tech ID: TEC2013-0117 Alternative contact due to temporary leave: Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.
- *Abstract
-
None
- *Principal Investigator
-
Name: Xuefei Huang, Professor
Department: Chemistry
Name: Peng Wang, Doctoral Student
Department: Chemistry
Name: Goran Larson
Department:
Name: Jonas Nilsson
Department:
- Country/Region
- USA
For more information, please click Here
